Partial Seizure – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Partial seizures, often referred to as
"focal seizures," primarily impact a specific brain region, with the
temporal lobes being the most common location of occurrence. They can be
categorized into two main types: simple partial seizures, which occur without a
loss of consciousness, and complex partial seizures, which involve impaired
consciousness. When a partial seizure extends to affect the entire brain, it is
termed a "partial seizure with secondary generalization." Partial
seizures are the most prevalent form of seizures among individuals with
epilepsy. Notably, complex partial seizures are more frequent than simple
partial seizures, though many complex partial seizures initially manifest as
simple partial seizures. Seizures result from episodes of excessive and
disorganized neuronal activity within the brain. Ordinarily, electrical signals
are conveyed through an action potential with a net influx of positive ions,
leading to neuron depolarization. Hyperexcitability is typically held in check
by various inhibitory mechanisms involving negative ions like chloride ions and
inhibitory neurotransmitters. Altered voltage-gated ion channels can disrupt
this balance, leading to heightened excitatory transmission and reduced
inhibitory signals, thereby causing hyperexcitability. Glutamate serves as the
primary excitatory neurotransmitter in the brain, while GABA acts as the
inhibitory counterpart. When excitation prevails over inhibition in neurons,
hyperexcitability occurs. The convergence of an epileptic focus,
hyperexcitability, and hyper-synchronization among neurons ultimately triggers
seizures. There is no drug of choice for treating seizures. Commonly employed
first-line medications for partial epilepsy encompass carbamazepine and
lamotrigine. Secondary options may be considered if these medications fail to
control seizures, including valproate, topiramate, oxcarbazepine, or
gabapentin. Notably, lamotrigine is the preferred treatment for partial
seizures associated with secondary generalization. Patients experiencing
partial seizures face a greater risk of seizure recurrence than those with
generalized seizures. However, recurrence rates appear similar between simple
and complex partial seizures. Furthermore, simple partial seizures, which do
not involve a loss of consciousness, carry a lower risk of seizure-related
complications such as aspiration and exhibit a reduced overall morbidity and
mortality rate compared to seizures that impair consciousness. Simple partial
seizures can also result in falls and injuries.
·
In the United States, partial seizures are
estimated to be around 20 cases per 100,000 individuals aged 1-65. According to
the CDC, approximately 3.4 million people in the United States are affected by
epilepsy, including 3 million adults and 470,000 children.
Thelansis’s “Partial Seizure Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Partial Seizure treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Partial Seizure across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Partial Seizure Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment